64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Trial Details

NCT ID

NCT04868604

Phase

PHASE1 / PHASE2

Sponsor

Clarity Pharmaceuticals Ltd

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• 64Cu-SAR-bisPSMA
• 67Cu-SAR-bisPSMA

Locations (sample)

• Stanford, California, United States|37.42411,-122.16608
• River Ridge, Louisiana, United States|29.9602,-90.21563
• Grand Rapids, Michigan, United States|42.96336,-85.66809
• Rochester, Minnesota, United States|44.02163,-92.4699
• St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

• Signed informed consent;
• ≥18 years of age;
• Eastern Cooperative Oncology Group performance status of 0 to 2;
• Life expectancy \>6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.